当前位置: 首页 > 期刊 > 《新医学》 > 20196
编号:13547224
含奥沙利铂化学治疗方案对Ⅱ期结直肠癌患者肝纤维化的影响(4)
http://www.100md.com 2019年6月1日 《新医学》 20196
     [11]Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A.Dhalluin-Venier V. Fontaine H, Pol S. FIB-4 : an inexpensiveand accurate marker of fibrosis in HCV infection. comparisonwith liver biopsy and fibrotest. Hepatology, 2010, 46 ( l ) :32-36.

    [12]張瑾 ,张和平 . CT测量肝脏体积的临床意义 .中国医药指南 ,2010. 8 ( 26 ) : 37-38.

    [13] Kawai T. Yamazaki S. Iwama A, Higaki T, Sugitani M,Takayama T. Focal sinusoidal ohstruction syndrome caused byoxaliplatin-induced chemotherapy : a case report. Hepat Mon ,2016. 16 ( 9 ) : e37572.

    [14] Park S. Kim HY. Kim H. Park JH. Kim JH. Kim KH. KimW. Choi lS, Jung YJ, Kim JS. Changes in noninvasive liverfibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome.Medicine, 2016, 95 ( 2 ) : e2454.

    [15]卢悛竹 ,詹俊 .药肝所致肝窦阻塞综合征研究进展 .新医学 .2017, 48 ( 12 ) : 833-838. [16]Al-Batran SE. Homann N. Pauligk C, Goetze TO, Meiler J.Kasper S, Kopp HG, Mayer F, Haag CM, Luley K, LindigU. Schmiegel W, Pohl M. Stoehlmacher J, Folprecht G.Prohst S. Prasnikar N. Fischbach W. Mahlberg R, Trojan J,Koenigsmann M, Martens UM. Thuss-Patience P, Egger M,Block A, Heinemann V, Illerhaus C, Moehler M. Schenk M.Kullmann F. Behringer DM, Heike M, Pink D. Teschendorf C. Lohr C, Bernhard H. Schuch C. Rethwisch V. vonWeikersthal LF . Hartmann JT. Kneba M . Daum S. SchulmannK, Weniger J. Belle S. Gaiser T. Oduncu FS, Giintner M.Hozaeel W. Reichart A. Jager E. Kraus T, Monig S, BechsteinWO. Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIOInvestigators. Perioperative chemotherapy with fluorouracil plusleucovorin, oxaliplatin, and docetaxel versus fluorouracil orcapecitabine plus cisplatin and epirubicin for locally advanced ,resectable gastric or gastro-oesophageal junction adenocarcinoma( FIOT4 ) : a randomised, phase 2/3 trial. Lancet, 2019 Apr10. pii: S0140-6736 ( 18 ) 32557-1. doi: 10.1016/S0140-6736( 18 ) 32557-1. [ Epub ahead of print ]

    [17]Lu Y, Lin Y, Huang X, Wu S. Wei J, Yang C. Oxaliplatinaggravates hepatic oxidative stress , inflammation and fibrosis ina non-alcoholic fatty liver disease mouse model. Int J Mol Med.2019 Apr l. doi: 10.3892/ijmm.2019.4154. [ Epub ahead ofprint ], http://www.100md.com(梁承华 郑晓明 张亚琴 雷普润 蔡梓凯 魏波)
上一页1 2 3 4